Three Firms Aid Sixth Street, Royalty Pharma Invest in Blueprint

Goodwin is advising Massachusetts-based Blueprint Medicines Corporation on its agreements to get up to $1.25 billion in cash and financing from Sixth Street Capital and Royalty Pharma to expand its offering of cancer treatments.

Cooley is counseling private equity firm Sixth Street, which agreed to pay $250 million cash upfront for future royalties for two drugs, up to $400 million in senior secured credit, and another $260 million for a potential credit facility to support Blueprint’s acquisitions of assets, according to a statement.

Gibson, Dunn & Crutcher is advising pharmaceutical investor Royalty Pharma, which agreed to pay $175 million cash ...